News

Banca Monte dei Paschi di Siena (BMPS) is trading near €8.78, with a 7‑day share‑price return of 7.13 % and a 30‑day decline of 1.88 %. Over the past 12 months the bank’s total shareholder return has reached 52.79 %, indicating long‑term momentum despite short‑term volatility. The current price reflects a modest intrinsic discount of about 1 % agai...

Full article

Listed on the Euronext Paris Stock Exchange, BALYO continues to operate under new ownership while the AMF’s review proceeds. SoftBank’s bid price for the remaining shares stands at €0.60 per share, underscoring the company’s current market position and future prospects amid the ongoing regulatory scrutiny.

Full article

SoftBank’s acquisition of over 91 % of BALYO, completed in November 2024, has integrated the company into its ecosystem of intralogistics automation and robotics. The takeover has accelerated BALYO’s global expansion, now deploying more than 1,500 robots across more than 25 countries. The firm’s 2025 financial performance is highlighted with revenu...

Full article

BALYO has announced that an addendum to its report dated January 6 2026, prepared by independent expert Ledouble, is now available on its website. The addendum follows the Autorité des marchés financiers (AMF) requests for clarifications made during its review of the tender offer and squeeze‑out that SoftBank Group initiated. Minority shareholders...

Full article

Vitalik Buterin, co‑founder of Ethereum, has cautioned that prediction‑market platforms are shifting toward a “corposlop” model that prioritizes profit over consumer welfare. He attributes this trend to a heavy focus on short‑term price speculation and sports‑betting activities, which generate revenue during bear markets but erode market integrity....

Full article

On Monday, Vanda Pharmaceuticals’ shares surged 33 % after the U.S. FDA approved Bysanti (milsaperidone) for treating bipolar I disorder and schizophrenia. Bysanti is the active metabolite of Fanapt (iloperidone) and has shown bioequivalence to the parent drug. The approval is seen as a turning point for Vanda, which had previously traded at a disc...

Full article

National Vision (EYE) holds a Zacks Rank of #2 (Buy), reflecting strong earnings estimate revisions, while Hermes International SA – Unsponsored ADR (HESAY) carries a #4 (Sell) ranking. EYE’s forward price‑to‑earnings ratio is 30.39, notably lower than HESAY’s 45.24, indicating a less expensive valuation relative to expected earnings. The PEG ratio...

Full article

Looking ahead, Tandem forecasts modest but profitable growth for 2026, projecting full‑year sales between $1.065 billion and $1.085 billion and gross margins of 56% to 57%. The company attributes its improving financials to a new pay‑as‑you‑go pharmacy model in the United States, which is shifting its revenue stream toward more predictable and high...

Full article

Tandem Diabetes Care’s shares rose over 32% after the company released its fourth‑quarter earnings, which showed a 3% year‑over‑year revenue increase to $290 million. Worldwide insulin‑pump shipments reached 38,000 units, including 27,000 in the United States, reflecting the continued demand for its devices.

Full article

The company’s fundamentals remain solid, with a 4 % dividend yield and expected revenue growth of 1.78 % next year. Investor sentiment is positive, with 439 Motley Fool followers and 15,600 Seeking Alpha users rating HST “Strong Buy.” Short interest is low at 4.20 % of the float, 3.06 days to cover.

Full article